Asia-Pacific CRO Novotech makes US play with NCGS acquisition

Asia-Pacific CRO Novotech is getting into business on this side of the world with the acquisition of South Carolina-based clinical services company NCGS.

That means Novotech can now offer services in the U.S., specifically for later-phase global studies, the company said Wednesday. Financial details of the transaction were not disclosed.

NCGS is a privately held CRO that has a workforce of about 300 people across the U.S. The company focuses on oncology, hematology, infectious disease and central nervous system disorders in adults and pediatric populations.

Novotech has hundreds of sites in the Asia-Pacific, which will be complemented by the addition of NCGS’ broad U.S. site base.

“This is a strategic move to provide U.S.-based expertise and infrastructure for our U.S. clients wanting trials in APAC and the U.S., and for our APAC clients wanting U.S. clinical programs,” said Novotech CEO John Moller, M.D.

Novotech and NCGS have worked together for over a decade, according to NGCS founder and CEO Nancy Snowden.

Back in 2020, Novotech turned a partnership with Shanghai-based PPC Group into a full merger, bringing together 1,550 employees focused on biotech in Asia.